Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2010 |
| End Date: | June 2013 |
Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)
This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in
relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple
myeloma. The study will be conducted in two stages with 5-6 patients in each indication in
Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.
We found this trial at
1
site
New Brunswick, New Jersey 08903
Click here to add this to my saved trials
